Company / Financials
Tempest Therapeutics, Inc. Financials
FY2015-FY2017 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$277.0K
FY2017
Net Income
-$73.2M
FY2017 · -47.9% YoY
Profit Margin
-26432.9%
FY2017 · net income / revenue
ROE
-113.9%
FY2017 · return on equity
Total Assets
$72.9M
FY2017
Total Debt
-
FY2017
Equity
$64.3M
FY2017
ROA
-100.5%
FY2017 · return on assets
Statement paths
Financial highlights
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.69 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$277.0KNet Income HistoryProfit after all expenses and taxes-$73.2M-47.9% YoYCost of Revenue HistoryDirect costs of producing goods and services sold$2.2MOperating Income HistoryProfit from core business operations before interest and taxes-$72.0M-50.2% YoYSG&A Expense HistorySelling, general, and administrative expenses$51.6M+97.3% YoYR&D Expense HistoryResearch and development spending$18.4M-15.4% YoYIncome Tax HistoryTotal income tax expense$75.0KEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$2.70-23.3% YoYShares Outstanding HistoryWeighted average diluted shares outstanding35.6M+30.6% YoYTotal Assets HistoryTotal value of all assets owned$72.9M-40.5% YoY